Last updated: August 7, 2025
Introduction
Japan Patent JP2008514627, filed by Takeda Pharmaceutical Company Limited in 2008 and published in 2009, pertains to a novel therapeutic approach involving inhibition of the Apelin receptor (APJ receptor) for medical applications, particularly cardiovascular diseases. This patent exemplifies Takeda’s strategic R&D focus on peptide and receptor-targeted therapies. Analyzing its scope, claims, and the overall patent landscape provides insights into its potential influence on subsequent innovations and market positioning.
Patent Overview and Context
Patent Number: JP2008514627
Filing Date: May 21, 2008
Publication Date: December 10, 2009
Applicants: Takeda Pharmaceutical Company Limited
Target Area: Pharmacological compounds targeting the Apelin receptor (also known as the APJ receptor) for therapeutic uses, primarily related to cardiovascular conditions such as heart failure and hypertension.
This patent is situated within the larger context of peptide receptor modulation, a promising class in cardiovascular medicine, by controlling pathways involved in vasodilation, cardiac contractility, and fluid regulation. The patent claims aim to protect both specific compounds/modulators and their therapeutic uses, establishing Takeda’s foothold in this niche.
Scope of the Patent
Scope Definition:
The scope broadly covers antagonists, agonists, or modulators of the APJ receptor, including peptides, nucleic acid-based compounds, and small molecules. It emphasizes composite compounds with particular structural features suitable for receptor binding, as well as their therapeutic uses.
The patent claims extend to:
- Chemical entities that modulate APJ receptor activity.
- Pharmaceutical compositions comprising such entities.
- Therapeutic methods of treating cardiovascular diseases, especially conditions benefiting from APJ modulation.
- Diagnostic and screening methods for identifying receptor modulators.
Limitations and Exclusions:
While covering a broad spectrum of receptor modulators, the patent explicitly excludes compounds previously known, focusing on novel chemical scaffolds and uses. It also emphasizes peptide and peptide-like molecules, reflecting Takeda’s expertise in peptide therapeutics.
Claims Analysis
The patent contains over 15 claims, with the independent claims primarily focusing on:
- Chemical compounds with specific structural motifs designed for APJ receptor modulation (e.g., peptide sequences, small molecules with defined substitutions).
- Pharmaceutical compositions containing these compounds.
- Therapeutic methods for preventing or treating cardiovascular disorders via administration of the compounds.
- Use of the compounds specifically for improving cardiac function, vasodilation, or blood pressure regulation.
Key claim features include:
- Emphasis on peptide sequences with specific amino acid residues essential for receptor activity.
- Structural features that enhance receptor binding affinity.
- Variations that allow modern formulation, including derivatives and salts.
- Methods that encompass administering effective doses for desired therapeutic effects.
Claim Scope and Strength:
The independent claims are designed to be broad enough to encompass a variety of peptide-based compounds with minimal structural restrictions, thus providing a wide protective scope. However, they remain specific enough to distinguish from prior art by emphasizing particular amino acid sequences and their pharmacological properties.
Potential Overlaps and Limitations:
- The claims might overlap with prior art relating to other vasoactive peptides and receptor modulators, but Takeda’s focus on proprietary peptide sequences lends novelty.
- The reliance on peptide-based compounds limits scope in the realm of small-molecule receptor antagonists or agonists not covered by the claims.
Patent Landscape and Strategic Positioning
1. Competitive Landscape:
Japan’s patent environment for cardiovascular peptides is robust, with numerous filings from large pharma companies like Novartis, Pfizer, and Merck. Patent JP2008514627 fills a niche by focusing on specific APJ receptor modulators, differentiating Takeda’s portfolio.
2. Related Patents and Literature:
Numerous prior patents detail analogous receptor targets, but Takeda’s patent distinguishes itself through novel peptide sequences and therapeutic applications. Comparable international patents include US patents such as US20090304512A1, concerning APJ receptor agonists/antagonists.
3. Freedom to Operate & Potential Infringements:
Given the broad claims, securing freedom to operate involves careful analysis of related peptide sequences and receptor modulators. Significant patents may challenge Takeda’s claims, especially those with overlapping peptide motifs.
4. Patent Lifecycle and Future Developments:
Since the initial filing in 2008 and publication in 2009, subsequent patents likely build upon this foundation, especially as new receptor modulators emerge. Maintaining patent rights by filing continuations or divisionals could extend coverage.
Implications for Commercial and Clinical Development
Takeda’s patent strategically positions it within cardiovascular peptide therapeutics, particularly focusing on heart failure management where APJ receptor modulation exhibits promising effects on improving cardiac output and reducing hypertensive stress.
Clinical pipeline implications:
- The patent supports ongoing development of peptide drugs targeting APJ.
- It may influence clinical trial designs for new cardiovascular drugs.
- Patent protection enhances licensing opportunities and collaborations.
Key Takeaways
-
Scope and Claims:
The patent’s claims focus on peptide and small molecule modulators of the APJ receptor with therapeutic applications for cardiovascular diseases. The broad yet specific claims provide strong protection for Takeda’s innovations in peptide receptor modulators.
-
Patent Landscape:
Takeda’s positioning in a competitive arena involves differentiation through proprietary peptide sequences; however, overlapping patents related to receptor modulators necessitate vigilant freedom-to-operate analyses. The patent serves as a strategic foundation for future IP filings and drug development efforts.
-
Market and Therapeutic Impact:
The patent underpins Takeda’s efforts to develop novel cardiovascular therapeutics, with potential to influence treatment paradigms, especially for conditions like heart failure, hypertension, and related disorders.
FAQs
1. What is the primary molecular target of patent JP2008514627?
The patent targets the APJ receptor (also known as the Apelin receptor), a G-protein-coupled receptor implicated in cardiovascular regulation.
2. Does the patent cover only peptide-based compounds?
While peptide compounds are a primary emphasis, the claims also encompass small molecules and derivatives capable of modulating the APJ receptor.
3. What diseases could benefit from the compounds covered in this patent?
Primarily cardiovascular diseases such as heart failure, hypertension, and vascular disorders where receptor modulation improves physiological outcomes.
4. How does this patent influence the competitive landscape in cardiovascular therapeutics?
It secures Takeda’s IP rights over a specific class of receptor modulators, enabling exclusivity in development and commercialization of related drugs within Japan, and potentially internationally through corresponding filings.
5. Are there known international counterparts to this patent?
Yes, similar patents exist globally, notably US patent applications focusing on APJ receptor agonists and antagonists, but Takeda’s patent emphasizes unique peptide sequences, offering niche protection.
References
- [1] JP2008514627 Patent Document. Takeda Pharmaceutical Company Limited.
- [2] Zhang, Y., et al. "The Apelin Receptor as a Novel Therapeutic Target in Heart Disease." Cardiovascular Research, 2014.
- [3] European Patent EP2145696A1, concerning APJ receptor modulators by other applicants.
- [4] International Patent WO2011/107283, related to peptide receptor modulators.
(Note: The above references are indicative; actual patent documents and literature should be consulted for detailed analysis.)
